Biohaven Pharmaceutical Holding Company Ltd. Aktie News

Biotech stocks are full of intriguing innovators who could help pave the way for greater gains over the years ahead. Undoubtedly, it's virtually impossible to tell exactly which pills, shots and treatments within a firm's pipeline will eventually evolve into cash flows, let alone blockbuster cash cows.

As tech giants and other sector leaders report their most recent quarterly results, one might expect notable insider purchases to be scarce.

If you follow Warren Buffett's advice of being greedy when others are fearful, then it probably makes sense to consider biotech stocks to buy on the dip. Primarily, the thesis centers on the underlying necessity of the ecosystem.

NEW HAVEN, Conn. , April 22, 2024 /PRNewswire/ -- Biohaven Ltd.

NEW HAVEN, Conn. , April 18, 2024 /PRNewswire/ -- Biohaven Ltd.

NEW HAVEN, Conn. , April 17, 2024 /PRNewswire/ -- Biohaven Ltd.

Biohaven's first-in-class Molecular Degrader of Extracellular Proteins (MoDE™) technology targeting IgG removal, BHV-1300, was selected for an oral presentation at AAN highlighting its novel mechanism of action and the latest preclinical data demonstrating rapid, robust, and selective target removal Biohaven announces it will present safety and IgG lowering data from its ongoing single ascendin...

Driving clinical, regulatory, and operational excellence across five innovative platforms focused on immunology, neuroscience, and oncology: Portfolio targeting large indications including obesity, epilepsy, bipolar disorder, depression, obsessive-compulsive disorder (OCD), migraine, pain, Alzheimer's disease, Parkinson's disease, multiple sclerosis, rheumatoid arthritis, and cancer. Also advan...